Bioactive Lipids as Chronic Myeloid Leukemia's Potential Biomarkers for Disease Progression and Response to Tyrosine Kinase Inhibitors

Autor(es):Mostrar menos -

de Almeida, Felipe Campos ; Berzoti-Coelho, Maria G. ; Toro, Diana Mota ; Cacemiro, Maira da Costa ; Bassan, Vitor Leonardo ; Barretto, Gabriel Dessotti ; Marques Garibaldi, Pedro Manoel ; Palma, Leonardo Carvalho ; De Figueiredo-Pontes, Lorena Lobo ; Sorgi, Carlos Arterio ; Faciolli, Lucia Helena ; Gardinassi, Luiz Gustavo ; de Castro, Fabiola Attie

• Tipo de documento: Artigo Científico
• Fonte: FRONTIERS IN IMMUNOLOGY; v. 13, p. 8-pg., 2022-04-13.

Resumo

Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm that expresses the Philadelphia chromosome and constitutively activated Bcr-Abl tyrosine kinase in hematopoietic progenitor cells. Bcr-Abl tyrosine-kinase inhibitors (TKI) do not definitively cure all CML patients. The efficacy of TKI is reduced in CML patients in the blastic phase-the most severe phase of the disease-and resistance to this drug has emerged. There is limited knowledge on the underlying mechanisms of disease progression and resistance to TKI beyond BCR-ABL1, as well as on the impact of TKI treatment and disease progression on the metabolome of CML patients. The present study reports the metabolomic profiles of CML patients at different phases of the disease treated with TKI. The plasma metabolites from CML patients were analyzed using liquid chromatography, mass spectrometry, and bioinformatics. Distinct metabolic patterns were identified for CML patients at different phases of the disease and for those who were resistant to TKI. The lipid metabolism in CML patients at advanced phases and TKI-resistant patients is reprogrammed, as detected by analysis of metabolomic data. CML patients who were responsive and resistant to TKI therapy exhibited distinct enriched pathways. In addition, ceramide levels were higher and sphingomyelin levels were lower in resistant patients compared with control and CML groups. Taken together, the results here reported established metabolic profiles of CML patients who progressed to advanced phases of the disease and failed to respond to TKI therapy as well as patients in remission. In the future, an expanded study on CML metabolomics may provide new potential prognostic markers for disease progression and response to therapy. (AU)

• Processo FAPESP: 14/50947-7 - INCT 2014: em Células Tronco e Terapia Celular no Câncer
• Beneficiário: Dimas Tadeu Covas
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 15/21866-1 - Regulação da célula-tronco hematopoética normal e neoplásica mediada por citocinas secretadas pelas células natural killer
• Beneficiário: Lorena Lôbo de Figueiredo Pontes
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores
• Processo FAPESP: 18/19714-7 - Influência das alterações das células estromais mesenquimais multipotentes da medula óssea na fisiopatologia e progressão das neoplasias mieloproliferativas BCR-ABL1-
• Beneficiário: Fabíola Attié de Castro
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 15/23555-3 - MicroRNAs reguladores da via HIPPO em Leucemia Mielóide Crônica
• Beneficiário: Maria Gabriela Berzoti Coelho
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 15/00658-1 - Novos aspectos funcionais dos eicosanóides
• Beneficiário: Lúcia Helena Faccioli
• Modalidade de apoio: Auxílio à Pesquisa - Programa Equipamentos Multiusuários
• Processo FAPESP: 13/08135-2 - CTC - Centro de Terapia Celular
• Beneficiário: Dimas Tadeu Covas
• Modalidade de apoio: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs
• Processo FAPESP: 18/01756-5 - Caracterização Imunológica e Funcional das Células Estromais Mesenquimais Multipotentes em Neoplasias Mieloproliferativas
• Beneficiário: Maira da Costa Cacemiro
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado